Azithromycin combination therapy for community-acquired pneumonia: propensity score analysis

Area of Science:

• Infectious Diseases
• Pulmonology
• Clinical Pharmacology

Background:

• Severe community-acquired pneumonia (CAP) management in non-intensive care units (ICU) often involves β-lactam monotherapy.
• The role of adding macrolides, such as azithromycin, to β-lactam regimens for non-ICU CAP patients requires further clarification.

Purpose of the Study:

• To evaluate the efficacy of adding azithromycin to β-lactam antibiotics in reducing 30-day mortality for hospitalized non-ICU patients with severe CAP.
• To compare combination therapy versus β-lactam monotherapy using various severity classification criteria.

Main Methods:

• Prospective cohort study of consecutive CAP patients hospitalized in non-ICU settings (October 2010 - November 2016).
• Comparison of 30-day mortality between β-lactam/azithromycin combination and β-lactam monotherapy.
• Patient stratification using CURB-65, Pneumonia Severity Index (PSI), and Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) criteria.
• Inverse probability of treatment weighting (IPTW) analysis to control for confounding factors.

Main Results:

• Combination therapy did not significantly reduce 30-day mortality based on CURB-65 and PSI criteria.
• However, based on IDSA/ATS criteria, azithromycin combination therapy significantly decreased 30-day mortality in severe CAP patients (OR 0.12).
• No significant mortality reduction was observed for non-severe pneumonia patients using IDSA/ATS criteria (OR 1.85).
• IPTW analysis confirmed these findings.

Conclusions:

• Azithromycin combination therapy is associated with significantly reduced 30-day mortality in severe CAP patients who meet IDSA/ATS criteria.
• The benefit of macrolide combination therapy may be criterion-dependent for non-ICU CAP patients.